Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

COVID-19 Vaccination Remains Imperative for Patients with Cancer

November 4th 2021

As the COVID-19 pandemic persists, patients with cancer should receive the full vaccination with 1 of the 3 approved COVID-19 vaccines as soon as they are able, according to Steven Ludlow, PharmD, BCOP, BCPS.

Treatment Options Continue to Increase in Low-Risk MDS

November 3rd 2021

Azanucleosides, such as azacitidine, remain the backbone of disease-modifying therapy for patients with myelodysplastic syndromes, however, new adjuncts are leading to longer remissions and disease-free survival in patients with low-risk disease.

The Multifaceted Threat of Cyberattacks in Oncology

November 1st 2021

Diego Adrianzen Herrera, MD, shares his experience with a cyberattack at the University of Vermont Health Network and its effect on inpatient and outpatient care delivery.

First-Line Durvalumab Aims to Add Additional Treatment Option in Malignant Pleural Mesothelioma

October 29th 2021

Investigators look to boost systemic therapy options for patients with malignant pleural mesothelioma with the phase 3 DREAM3R trial.

Tisotumab Vedotin Displays Efficacy, Tolerability in Cervical Cancer

October 27th 2021

The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.

Cemiplimab Expands Treatment Portfolio for Patients with Basal Cell Carcinoma

October 27th 2021

Alexander J. Stratigos, MD, PhD, discussed the effect cemiplimab will have on the treatment landscape of patients with advanced BCC.

Cemiplimab Earns High Marks in First-Line Treatment of Advanced NSCLC

October 18th 2021

Ahmet Sezer, MD, discusses how the approval of cemiplimab could potentially make a huge impact for patients with advanced non–small cell lung cancer.

Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial

October 14th 2021

The initiation of the phase 3 ENHANCE trial looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody, for patients with intermediate-, high-, and very high–risk myelodysplastic syndrome.

Onvansertib Combination Aims to Improve Poor Prognosis in PDAC

October 7th 2021

Patients with pancreatic ductal adenocarcinoma experience limited benefit with available first- and second-line second line of therapy.

Lenvatinib Plus Pembrolizumab Makes an Impression in Advanced RCC

October 6th 2021

Robert J. Motzer, MD, spoke about the “exceptional” efficacy of the combination and how it fits into the evolving RCC treatment landscape.

Pivotal MagnetisMM-3 Trial Aims to Add Elranatamab in Multiple Myeloma Treatment

September 27th 2021

Patients with relapsed/refractory multiple myeloma, particularly those who have failed a prior BCMA–targeted therapy, represent a population with an unmet need for effective treatment options. Investigators are hoping to help fill this void with the initiation of the phase 2 MagnetisMM-3 study.

Balstilimab Plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Erdafitinib Plus Cetrelimab Exhibits Encouraging Efficacy in Metastatic Urothelial Cancer

September 17th 2021

Erdafitinib in combination with cetrelimab displayed clinically meaningful responses in patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations.

Promising Results Push Nivolumab/Chemotherapy Forward in Gastric Cancer

September 15th 2021

Jaffer A. Ajani, MD, unpacks the performance of nivolumab in combination with chemotherapy in some subgroups of gastric cancer.

LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach

September 14th 2021

Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.

Lutetium-PSMA Appears Safe in Locally Advanced High-Risk Prostate Cancer

September 11th 2021

Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.

Atezolizumab plus Chemotherapy Displays Efficacy, Tolerability in NSCLC with Untreated Brain Metastases

September 10th 2021

Atezolizumab plus carboplatin and pemetrexed yielded a favorable safety and efficacy profile in patients with advanced non-squamous non-small cell lung cancer with untreated brain metastases.

ADP-A2AFP SPEAR T Cells Demonstrate Efficacy, Tolerability in Advanced HCC

September 7th 2021

ADP-A2AFPspecific peptide enhanced affinity receptor T cells were associated with an acceptable safety profile and elicited antitumor activity in patients with advanced hepatocellular carcinoma.

New Strategies for RET Inhibition May Expand Their Role in NSCLC

July 30th 2021

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

Infigratinib Opens Up Options for Patients With FGFR2-Mutant Cholangiocarcinoma

July 29th 2021

Milind Javle, MD, discusses the potential impact of infigratinib on the treatment landscape of FGFR2 fusion–positive cholangiocarcinoma.

NEXT PAGE
PREVIOUS PAGE